Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

Pier Luigi Zinzani, MD, PhD, Enrico Derenzini, MD, Cinzia Pellegrini, Luigi Rigacci, Alberto Fabbri, Federica Quirini, Vittorio Stefoni, Letizia Gandolfi, Lisa Argnani, Beatrice Casadei, Alessandro Broccoli, Alessandro Pulsoni, MD, Marco Gobbi, MD, Alessio Perrotti, Alfonso Zaccaria, Maria Teresa Voso, MD, Maria Giuseppina Cabras, Amalia De Renzo, Michele Baccarani, MD

Blood (2011) 118 (21): 1604.

https://doi.org/10.1182/blood.V118.21.1604.1604

Published: 2011

Journal Articles

A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

Pier Luigi Zinzani, MD, PhD, Monica Tani, MD, Stefano Fanti, MD, Gerardo Musuraca, MD, Alessio Perrotti, MD, Umberto Vitolo, MD, Mariapaola Fina, MD, Barbara Botto, MD, Enrica Marchi, MD, Giulia Benevolo, MD, Vittorio Stefoni, MD, Michele Baccarani, MD,PhD

Blood (2006) 108 (11): 2478.

https://doi.org/10.1182/blood.V108.11.2478.2478

Published: 2006

Journal Articles

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

Pier Luigi Zinzani, MD, PhD, Alessandro Pulsoni, MD, Manuela Balocco, MD, Monica Tani, MD, Stefano Fanti, MD, Alessio Perrotti, MD, Paolo Castellucci, MD, Francesco Zaja, MD, Alberto Fabbri, MD, Alfonso Zaccaria, MD, Maria Teresa Voso, MD, Pierpaolo Fattori, MD, Luciano Guardigni, MD, Patrizia Gentilini, MD, Maria Giuseppina Cabras, MD, Amalia De Renzo, MD, Luigi Rigacci, MD

Blood (2006) 108 (11): 2479.

https://doi.org/10.1182/blood.V108.11.2479.2479

Published: 2006

Journal Articles

Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).

Marco Ladetto, Sonia Vallet, Paolo Corradini, Fabio Benedetti, Umberto Vitolo, Maurizio Martelli, Vincenzo Callea, Paolo Coser, Alessio Perrotti, Caterina Patti, Giuseppe Fioritoni, Sergio Morandi, Maurizio Musso, Renato Zambello, Monica Astolfi, Alessandro Pileri, Mario Boccadoro, Corrado Tarella

Blood (2004) 104 (11): 903.

https://doi.org/10.1182/blood.V104.11.903.903

Published: 2004

Journal Articles

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Blood (2002) 100 (5): 1559–1565.

https://doi.org/10.1182/blood-2002-02-0621

Published: 2002

NARROW

Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Email alerts

ASH Publications

American Society of Hematology

Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumumab Tiuxetan in Untreated Patients with Follicular Lymphoma. Long Term Efficacy and Toxicity Results of the FLUMIZ Trial.

A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.

A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Follicular Lymphoma (FL) Patients.

Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).

High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only